{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06054893",
            "orgStudyIdInfo": {
                "id": "408-C-2001"
            },
            "organization": {
                "fullName": "Biogen",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of Omaveloxolone in Children With Friedreich's Ataxia",
            "officialTitle": "An Open-Label, Phase 1, Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Pharmacodynamics, and Efficacy of Omaveloxolone in Participants \u22652 to <16 Years of Age With Friedreich's Ataxia",
            "acronym": "BOLD",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-omaveloxolone-in-children-with-friedreich-s-ataxia"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2030-02-21",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2030-02-21",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-13",
            "studyFirstSubmitQcDate": "2023-09-19",
            "studyFirstPostDateStruct": {
                "date": "2023-09-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-05",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Reata, a wholly owned subsidiary of Biogen",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The part 1 primary objective of the study is to evaluate the pharmacokinetics (PK) of omaveloxolone following administration of a single dose in 3 age cohorts (\u22652 to \\<6 years, \u22656 to \\<12 years, and \u226512 to \\<16 years) and secondary objective is to evaluate safety and tolerability of drug. The part 2 primary objective is to evaluate long term safety and tolerability of omaveloxolone.",
            "detailedDescription": "Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen. Recruitment will be limited to the U.S. only as participants will be able to remain on Part 2 of the study until they turn 16 and can access commercially-available drug which is FDA approved for age 16 and above."
        },
        "conditionsModule": {
            "conditions": [
                "Friedreich Ataxia"
            ],
            "keywords": [
                "Friedreich's ataxia",
                "FA",
                "RTA 408",
                "Omaveloxolone"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 and 2: Cohort A1",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort A1 will contain participants \u226512 to \\<16 years of age. Participants will receive a single oral dose of omaveloxolone 150 milligrams (mg), capsule, on Day 1 of the treatment period of part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian population pharmacokinetics (popPK) analyses.",
                    "interventionNames": [
                        "Drug: Omaveloxolone"
                    ]
                },
                {
                    "label": "Part 1 and 2: Cohort A2",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort A2 will contain participants \u226512 to \\<16 years of age. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from Cohort A1 to select the dose in part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses.",
                    "interventionNames": [
                        "Drug: Omaveloxolone"
                    ]
                },
                {
                    "label": "Part 1 and 2: Cohort B",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort B will contain participants \u22656 to \\<12 years of age and will initiate in parallel with Cohort A2. Participants will receive a single oral dose of omaveloxolone, capsule, at a dosage level determined by a Bayesian popPK analysis using the data from Cohort A1 to select the dose in part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses.",
                    "interventionNames": [
                        "Drug: Omaveloxolone"
                    ]
                },
                {
                    "label": "Part 1 and 2: Cohort C",
                    "type": "EXPERIMENTAL",
                    "description": "Cohort C will contain participants \u22652 to \\<6 years of age. Participants will receive a single oral dose of omaveloxolone at a dosage level determined by a Bayesian popPK analysis using the data from cohorts A1, A2, and B to select the dose in part 1 followed by the same dose in part 2 up to week 240 or commercial availability whichever comes first. The dose in part 2 may be adjusted as per additional safety and Bayesian popPK analyses.",
                    "interventionNames": [
                        "Drug: Omaveloxolone"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Omaveloxolone",
                    "description": "Administered as specified in the treatment arm",
                    "armGroupLabels": [
                        "Part 1 and 2: Cohort A1",
                        "Part 1 and 2: Cohort A2",
                        "Part 1 and 2: Cohort B",
                        "Part 1 and 2: Cohort C"
                    ],
                    "otherNames": [
                        "RTA 408",
                        "SKYCLARYS"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Apparent Clearance (CL/F) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Maximum Concentration (Cmax) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Volume of Distribution (V/F) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Area Under the Plasma Concentration-Time Curve From 0 Extrapolated to Infinity (AUC0-\u221e) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Area Under the Plasma Concentration-Time Curve From 0 to tlast (AUC0-tlast) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Area Under the Plasma Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Individual Steady-State AUC0-24 (AUC0-24,ss) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Individual Steady-State Cmax (Cmax,ss) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 1: Concentration at the end of a 24-Hour Dosing Interval (Ctrough,ss) of Omaveloxolone",
                    "timeFrame": "Predose (0 hour), after dose 1 hour, 2 hours, 3 hours, 4 hours, 24 hours, and 96 hours"
                },
                {
                    "measure": "Part 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)",
                    "description": "An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal (investigational) product, whether or not related to medicinal (investigational) product. SAE is any untoward medical occurrence that at any dose results in death, in the view of investigator, places the participant at immediate risk of death (life-threatening event), requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in congenital anomaly/birth defect or is medically important event.",
                    "timeFrame": "From Day 1 up to the end of study (up to Week 240)"
                },
                {
                    "measure": "Part 2: Number of Participants With Clinically Significant Abnormality in Clinical Laboratory Assessments",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Clinically Significant Abnormality in Vital Signs",
                    "description": "Vital signs, including blood pressure (BP), heart rate (HR), and oral body temperature, will be assessed.",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Clinically Significant Abnormality in Electrocardiograms (ECGs)",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Change from Baseline in Echocardiogram (ECHO)",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Change from Baseline in Height",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Change from Baseline in Weight",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Change from Baseline Body Mass Index",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Change from Baseline in Tanner Assessment",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Change from Baseline in Paediatric Growth (Height)",
                    "timeFrame": "From Day 1 up to Week 240"
                },
                {
                    "measure": "Part 2: Number of Participants With Change from Baseline in Paediatric Growth (Weight)",
                    "timeFrame": "From Day 1 up to Week 240"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants With AEs and SAEs",
                    "timeFrame": "From Day 1 up to Day 22"
                },
                {
                    "measure": "Part 1: Number of Participants With Abnormality in Clinical Laboratory Assessments",
                    "timeFrame": "From Day 1 up to Day 22"
                },
                {
                    "measure": "Part 1: Number of Participants With Abnormality in Vital Signs",
                    "timeFrame": "From Day 1 up to Day 22"
                },
                {
                    "measure": "Part 1: Number of Participants With Abnormality in ECGs",
                    "timeFrame": "From Day 1 up to Day 22"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Part 1:\n\nInclusion Criteria:\n\n* Have genetically confirmed FA.\n* Have a left ventricular ejection fraction \u2265 40% (based on ECHO performed at Screening Visit).\n* During screening, during the treatment period, and until 28 days following administration of the last dose of omaveloxolone, females of childbearing potential must practice at least 1 of the acceptable methods of birth control.\n* During screening, during the treatment period, and until 28 days after the last dose of omaveloxolone, fertile males who have female partners of childbearing potential must practice one of the acceptable methods of birth control.\n\nExclusion Criteria:\n\n* Have uncontrolled diabetes (HbA1c \\>11.0%).\n* Have B-type natriuretic peptide (BNP) level \\>200 picograms per milliliter (pg/mL) at screening.\n* Have a history of clinically significant (CS) left-sided heart disease and/or CS cardiac disease, with the exception of mild to moderate cardiomyopathy associated with FA.\n* Presence of outflow tract obstruction defined as a peak instantaneous gradient \\>50 mmHg (based off ECHO performed at screening).\n* Have taken any moderate or strong inhibitors and/or inducers of cytochrome P450 3A4 within the 7 days prior to Day 1 or plan to take during study participation (eg, itraconazole, carbamazepine, phenytoin, ciprofloxacin, grapefruit juice, cannabidiol, fluconazole, fluvoxamine, verapamil, diltiazem).\n* Have a history of CS liver disease (eg, fibrosis, cirrhosis, hepatitis), or have clinically relevant deviations in laboratory tests at screening\n* Plan to or have participated in any other interventional clinical study within the 30 days prior to Day 1.\n* Have a cognitive impairment that may preclude ability to comply with study procedures, in the opinion of the investigator.\n* Be unable to comply with the requirements of the study protocol or be unsuitable for the study for any reason, in the opinion of the investigator.\n* Have previously documented mitochondrial respiratory chain disease.\n* Have a history of thromboembolic events within the past 5 years.\n* Plan to or have taken anticoagulant therapy within 30 days prior to Day 1 with the exception of a daily low dose aspirin (up to 81 mg).\n* Plan to or have scheduled surgical treatment for scoliosis or foot deformity during the study.\n* Have had significant suicidal ideation within 30 days prior to Screening Visit, as per investigator judgment, or any history of suicide attempt.\n* For females, be pregnant or breastfeeding.\n\nPart 2:\n\n* No discontinuation criteria have been met.\n* Safety and tolerability data from Part 1 are supportive of continuation in the judgement of the Investigator.\n\nIn the event of intercurrent illness or other change in health status of the participant, additional Part 1 Screening assessments may be repeated prior to initiation of Part 2, based on the judgement of the Investigator in consultation with the Medical Monitor.\n\nNOTE: Other protocol- defined Inclusion/Exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "2 Years",
            "maximumAge": "15 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "US Biogen Clinical Trial Center",
                    "role": "CONTACT",
                    "phone": "866-633-4636",
                    "email": "clinicaltrials@biogen.com"
                },
                {
                    "name": "Global Biogen Clinical Trial Center",
                    "role": "CONTACT",
                    "email": "clinicaltrials@biogen.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Medical Director",
                    "affiliation": "Biogen",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital of Philadelphia",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19104",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Recruiting Coordinator",
                            "role": "CONTACT",
                            "phone": "800-879-8467"
                        },
                        {
                            "name": "David Lynch, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001259",
                    "term": "Ataxia"
                },
                {
                    "id": "D000002524",
                    "term": "Cerebellar Ataxia"
                },
                {
                    "id": "D000005621",
                    "term": "Friedreich Ataxia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020820",
                    "term": "Dyskinesias"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000002526",
                    "term": "Cerebellar Diseases"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000013132",
                    "term": "Spinocerebellar Degenerations"
                },
                {
                    "id": "D000013118",
                    "term": "Spinal Cord Diseases"
                },
                {
                    "id": "D000020271",
                    "term": "Heredodegenerative Disorders, Nervous System"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000028361",
                    "term": "Mitochondrial Diseases"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4565",
                    "name": "Ataxia",
                    "asFound": "Ataxia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8741",
                    "name": "Friedreich Ataxia",
                    "asFound": "Friedreich's Ataxia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5773",
                    "name": "Cerebellar Ataxia",
                    "asFound": "Ataxia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22574",
                    "name": "Dyskinesias",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M5775",
                    "name": "Cerebellar Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22510",
                    "name": "Spinocerebellar Ataxias",
                    "relevance": "LOW"
                },
                {
                    "id": "M15929",
                    "name": "Spinocerebellar Degenerations",
                    "relevance": "LOW"
                },
                {
                    "id": "M15915",
                    "name": "Spinal Cord Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M22092",
                    "name": "Heredodegenerative Disorders, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M23341",
                    "name": "Mitochondrial Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T2386",
                    "name": "Friedreich Ataxia",
                    "asFound": "Friedreich's Ataxia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5352",
                    "name": "Spinocerebellar Ataxia",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}